Lawsuits Filed Against WORX, CTMX and WFC – Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

SCWorx Corp. (NASDAQ:WORX)

CONTACT JAKUBOWITZ ABOUT WORX:
https://claimyourloss.com/securities/scworx-corp-loss-submission-form/?id=7609&from=1

Class Period : April 13, 2020 – April 17, 2020

Lead Plaintiff Deadline : June 29, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) SCWorx's supplier for COVID-19 tests had previously misrepresented its operations; (2) SCWorx's buyer was a small company that was unlikely to adequately support the purported volume of orders for COVID-19 tests; (3) as a result, the Company's purchase order for COVID-19 tests had been overstated or entirely fabricated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

CytomX Therapeutics, Inc. (NASDAQ:CTMX)

CONTACT JAKUBOWITZ ABOUT CTMX:
https://claimyourloss.com/securities/cytomx-therapeutics-inc-loss-submission-form/?id=7609&from=1

Class Period : May 17, 2018 – May 13, 2020

Lead Plaintiff Deadline : July 20, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program; (ii) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Wells Fargo & Company (NYSE:WFC)

CONTACT JAKUBOWITZ ABOUT WFC:
https://claimyourloss.com/securities/wells-fargo-company-loss-submission-form/?id=7609&from=1

Class Period : April 5, 2020 – May 5, 2020

Lead Plaintiff Deadline : August 3, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Wells Fargo planned to, and did, improperly allocate government-backed loans under the Paycheck Protection Program ("PPP"), and/or had inadequate controls in place to prevent such misallocation; (ii) the foregoing foreseeably increased the Company's litigation risk with respect to PPP allocation, as well as increased regulatory scrutiny and/or potential enforcement actions; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

ReleaseID: 595549